Trial-Results center  
Clinical trial results database in 100 Feedback    Home


Related trials

Buse, 2011 - exenatide vs placebo add on insulin

Lewin, 2010 - linagliptin vs placebo (add on to sulphonylurea)

DURATION-2 (Bergenstal) (vs sitagliptin), 2010 - exenatide vs sitagliptin

DURATION-3 (Diamant), 2010 - exenatide vs insulin glargine

Ratner DRI6012, 2010 - lixisenatide vs placebo add on MET

DURATION-2 (Bergenstal) (vs pioglitazone), 2010 - exenatide vs pioglitazone

Goodman, 2009 - vildagliptin vs placebo (add on to metformin)

HOME, 2009 - metformin vs placebo

LEAD-2 (Nauck) (vs placebo), 2009 - liraglutide vs placebo add on MET

Nauck (Sulf vs pbo), 2009 - vs placebo

9607, 2009 - exenatide vs placebo add on MET+/-SU

Li, 2009 - nateglinide vs repaglinide

LEAD-2 (vs MET), 2009 - liraglutide vs metformin

Ferrannini, 2009 - vildagliptin vs Sulfonylurea (add on to metformin)

LEAD-3 mono (Garber), 2009 - liraglutide vs glimepiride

Kaku, 2009 - mitiglinide vs placebo (on top pioglitazone )

COSMIC, 2009 - vs

LEAD-2 (Nauck) (vs glimepiride), 2009 - liraglutide vs glimepiride add on MET

DeFronzo, 2009 - saxagliptin vs placebo (add on to metformin)

RECORD, 2009 - rosiglitazone vs standard glucose-lowering drugs

Nauck, 2009 - alogliptin vs placebo (add on to metformin)

Nauck (vs GLP-1 analog), 2009 - vs GLP-1 analog

Filozof, 2009 - vildagliptin as add-on therapy vs gliclazide

Bolli, 2008 - vildagliptin vs pioglitazone (on top of metformin)

Moretto, 2008 - exenatide vs placebo



See also:

  • All test diab�te clinical trials
  • All diabetes clinical trials
  • All type 2 diabetes - sanofi clinical trials
  • All clinical trials of insulin secretagogues peptides (incretins)
  • All clinical trials of liraglutide
    		•  

    Feinglos study, 2005

    download pdf: liraglutide | insulin secretagogues peptides (incretins) for diabetes

    Treatments

    Studied treatment Liraglutide 0.045�0.75 mg daily
    Control treatment Metformin
    Concomittant treatment None

    Patients

    Patients subjects with Type 2 diabetes
    Baseline characteristics
    Age (year) 53  
    Duration of diabetes (year) 4.7 y 
    HbA1c (%) 7.0 
    BMI 34.5 
    Add-on to None 

    Method and design

    Randomized effectives 176 / 34 (studied vs. control)
    Blinding double blind (not adequate)
    Follow-up duration 12 weeks
    Remarks dose response study


    Results

    Endpoint Studied treat.
    n/N     Control treat.
    n/N     Graph RR [95% CI]

    severe hypoglycemia

    0 / 176
         0 / 34
         classic 0,19 [0,00;48,78]

    vomiting

    4 / 176
         1 / 34
         classic 0,77 [0,09;6,70]

    all hypoglycemia

    5 / 176
         2 / 34
         classic 0,48 [0,10;2,39]

    nausea

    7 / 176
         2 / 34
         classic 0,68 [0,15;3,12]

    All cause death

    0 / 176
         0 / 34
         classic 0,19 [0,00;48,78]     0 2 1.0

    Relative risks
    Endpoint Events (%) Relative Risk 95% CI Endpoint definition
    in the trial    		 Ref
    Studied treat. Control treat.
    severe hypoglycemia 0 / 176 (0,3%) 0 / 34 (1,5%) 0,19 [0,00;9,57] 12053
    vomiting 4 / 176 (2,3%) 1 / 34 (2,9%) 0,77 [0,09;6,70] 12053
    all hypoglycemia 5 / 176 (2,8%) 2 / 34 (5,9%) 0,48 [0,10;2,39] 12053
    nausea 7 / 176 (4,0%) 2 / 34 (5,9%) 0,68 [0,15;3,12] 0
    All cause death 0 / 176 (0,3%) 0 / 34 (1,5%) 0,19 [0,00;9,57] 12053
    The primary endpoint (if exists) appears in blod characters
    Reference(s) used for data extraction:
  • 12053: Monami M, Marchionni N, Mannucci EGlucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials.Eur J Endocrinol 2009;160:909-17
  • 0:

    • Endpoint studied treat. control treat. mean diff

    Absolute risk reduction
    Endpoint Events rate Absolute risk
    reduction (ARR)
    Studied treat. Control treat.
    vomiting 2,27% 2,94% -6,7‰
    all hypoglycemia 2,84% 5,88% -30,4‰
    nausea 3,98% 5,88% -19,1‰

    Meta-analysis of all similar trials:

    antidiabetic drugs in test diab�te for type 2 daibetes (NIDD)

    insulin secretagogues peptides (incretins) in diabetes for all type of patients

    insulin secretagogues peptides (incretins) in type 2 diabetes - sanofi for all type of patients



    Reference(s)

    Trials register # NA
    • Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of liraglutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes.. Diabet Med 2005;22:1016-23 - 10.1111/j.1464-5491.2005.01567.x
      Pubmed | Hubmed | Fulltext

    (c) 2004-2011 TrialResults-center - All Rights Reserved

    Tweet this  |  Facebook  |  notify a friend